Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study.

Anderson IM, Sarsfield A, Haddad PM.

J Affect Disord. 2009 Sep;117(1-2):116-9. doi: 10.1016/j.jad.2008.12.016. Epub 2009 Jan 25.

PMID:
19171384
2.

Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.

Bellino S, Paradiso E, Bogetto F.

J Clin Psychiatry. 2006 Jul;67(7):1042-6.

PMID:
16889446
3.

Quetiapine alone and added to a mood stabilizer for serious mood disorders.

Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattab H, Ray JB, Bingham CR.

J Clin Psychiatry. 2001 Sep;62(9):728-32.

PMID:
11681770
4.

Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.

Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A.

J Anxiety Disord. 2008 Dec;22(8):1480-6. doi: 10.1016/j.janxdis.2008.03.002. Epub 2008 Mar 13.

PMID:
18455360
5.

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.

Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group.

CNS Spectr. 2009 Jun;14(6):299-313.

PMID:
19668121
6.

Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.

Langosch JM, Drieling T, Biedermann NC, Born C, Sasse J, Bauer H, Walden J, Bauer M, Grunze H.

J Clin Psychopharmacol. 2008 Oct;28(5):555-60. doi: 10.1097/JCP.0b013e318185e75f.

PMID:
18794653
7.

Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.

Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A.

J Clin Psychiatry. 2005 Jan;66(1):73-9.

PMID:
15669891
8.

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group.

J Clin Psychopharmacol. 2006 Dec;26(6):600-9. Erratum in: J Clin Psychopharmacol. 2007 Feb;27(1):51.

PMID:
17110817
9.
10.
11.
12.

Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.

McManus DQ, Arvanitis LA, Kowalcyk BB.

J Clin Psychiatry. 1999 May;60(5):292-8.

PMID:
10362435
13.

A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.

Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vågerö M, Svensson K.

J Clin Psychiatry. 2005 Jan;66(1):111-21.

PMID:
15669897
14.

Long-Term use of quetiapine in elderly patients with psychotic disorders.

Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW.

Clin Ther. 2000 Sep;22(9):1068-84.

PMID:
11048905
15.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
16.

Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.

Sajatovic M, Mullen JA, Sweitzer DE.

J Clin Psychiatry. 2002 Dec;63(12):1156-63.

PMID:
12523876
17.
18.
19.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
20.

An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.

Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM.

Int Clin Psychopharmacol. 2006 Jan;21(1):11-20.

PMID:
16317312

Supplemental Content

Support Center